SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. The firm offers annealing and gate-model quantum computing technologies. It provides professional services that assist customers in identifying and implementing quantum computing applications and selling quantum computer systems to customers. The company was founded by Eric Ladizinsky in 1999 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

QBTS is drawing attention amid a steep selloff alongside other quantum-computing stocks, with traders citing high valuations, heavy losses and uncertainty over when the technology will generate meaningful commercial returns. Some see the decline as a buying opportunity, while others expect more downside and question whether upcoming results or company developments can reverse the trend.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a breakout to a fresh 52-week high, with traders positioning ahead of the Q3 report and watching BRIUMVI sales growth and guidance. Buyout and short-squeeze theories are also circulating, though some investors view the move as momentum ahead of earnings rather than evidence of a deal.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu shares are drawing attention after Lulas reelection triggered a sharp selloff across Brazilian stocks, with traders tying NUs decline to political and macroeconomic risk in its largest market rather than company-specific news. The community is split between viewing the move as an overreaction and buying opportunity, and expecting continued pressure from Brazil-related uncertainty.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have prompted concern about the slow launch of aldosterone-synthase inhibitors and the commercial outlook for Mineralys lorundrostat, contributing to MLYSs sharp decline. Some traders view the early sales as a coverage-access ramp rather than a verdict on demand, while others question whether Mineralys can compete and launch successfully on its own; its FDA decision remains a key milestone.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is falling amid a broad semiconductor selloff after Intels weak forward guidance heightened concerns about PC demand and industry conditions. Traders point to the drop across chip peers, while some see the pullback as a buying opportunity ahead of Qualcomms earnings report.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is drawing attention for heavy call-option activity, while traders debate whether bullish positioning can outweigh elevated jet-fuel costs and the reduced profit outlook. Strong travel demand and pricing power are seen as offsets, but the sustainability of margins remains uncertain.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in London, Canada.

Aduro Clean Technologies Inc

Attention centers on Aduros progress toward commercializing its Hydrochemolytic Technology, including pilot results on mixed polyolefin feedstocks and engineering work for its planned Chemelot facility; some investors also see paraffinic crude as a potential nearer-term application. Bullish holders view these as validation, while skeptics argue the company has yet to demonstrate viable economics or commercial-scale performance.

Charter Communications, Inc. engages in providing broadband communications services. Its services include Spectrum TV, Spectrum Internet, and Spectrum Voice. It offers business-to-business Internet access, data networking, business telephone, video and music entertainment services, and wireless backhaul. Its advertising sales division, Spectrum Reach, offers local, regional, and national businesses the opportunity to advertise in individual and multiple service areas on cable television networks and advanced advertising platforms. The company was founded in 1993 and is headquartered in Stamford, CT.

Charter Communications Inc. - Ordinary Shares - Class A

Charters Q2 results have intensified debate over persistent broadband subscriber losses, competition and heavy debt, with concerns about weaker cash generation and paused buybacks weighing on sentiment. Bulls counter that the stocks low valuation, mobile growth and the Cox merger could support a recovery, while others remain skeptical about the deals added financing and dilution.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

Discussion is focused on onsemis emerging AI/data-center exposure: traders point to growth in the Other end-market category, which includes computing and data centers, but question how durable that demand is because long-term supply agreements can be changed or canceled. The debate is tempered by the companys continued exposure to automotive and industrial markets facing a cyclical slowdown, alongside the stocks recent weakness.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons Q3 results beat expectations, with strong refining performance and war-related fuel-market disruptions lifting downstream results; the company also highlighted shareholder returns. The reaction is broadly positive, though some traders question whether the refining boost will last and point to put-heavy options activity as a sign of downside caution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.

Acrivon Therapeutics (ACRV) Expected to Announce Quarterly Earnings on Wednesday

Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six brokerages that are covering the company, Marketbeat.com...

Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Still a Buy?

Acrivon Therapeutics (NASDAQ:ACRV) Trading Up 3.2% - Should You Buy...

Research Analysts Set Expectations for ACRV Q1 Earnings

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for shares of Acrivon Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn...

Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold ratin...

Acrivon Therapeutics (NASDAQ:ACRV) Releases Earnings Results, Meets Estimates

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, meeting the consensus...

Acrivon Therapeutics (ACRV) Projected to Post Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-26-acrivon-therapeutics-inc-stock...

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Acrivon Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.66
Prev Close	$1.76
Open	$1.74
Dividend Yield	0.00%
50-Day Moving Average	$1.94
Beta	1.90
Avg. Volume	311,801.85
PE Ratio	-0.88

52-Week High	$3.56
52-Week Low	$1.27
Market Capitalization	$71.14M
EPS (Annual)	-$2.02
Price to Book	0.82
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACRV Fundamentals